Abstract
To review evidence on health utility scores and disability weights of liver cancer and related diseases in China. Structured literature searching was conducted in PubMed, EMbase, The Cochrane Library, Web of Science, CNKI, WanFang Data, CBM and VIP from inception to November, 2017. Two reviewers independently carried out literature screening, data extraction, descriptive analysis and risk of bias assessment via AHRQ, then meta-analysis was performed through Stata 12.0 software. A total of 9 studies were included, the overall quality was fine (9 out of 11 items were qualified), and EQ-5D was the most common tool in these studies. More than 10 related diseases were covered, among which chronic hepatitis B, compensated cirrhosis, decompensated cirrhosis and liver cancer were the mostly reported. Results of Meta-analysis showed that healthy utility scores of the four common diseases were 0.789 (0.735, 0.843), 0.734 (0.693, 0.776), 0.647 (0.627, 0.666) and 0.636 (0.508, 0.765), respectively; Results of Meta-analysis of health utility mesured by EQ-5D were 0.815 (0.762, 0.868), 0.761 (0.731, 0.791), 0.643 (0.62, 0.666) and 0.62 (0.473, 0.766), respectively. In addition, the corresponding median (range) utility scores of the four diseases were found to be 0.758 (0.520~0.950), 0.716 (0.570~0900), 0.538 (0.260~0.662) and 0.541(0.310~0.720. Only one disability weight study was concluded (0.36-0.90 reported for liver cancer). In Chinese population, current evidence on health utility of liver cancer and related diseases is limited, particularly data on disability weights. Health utility scores from Meta-analysis seem more optimistic and more centralized than those from descriptive analysis. Different survey tools bring out various outcomes, and attentions should be paid to their application. Health utility scores decrease with the severity of liver disease, which suggests that early prevention, early diagnosis and treatment may save more life years with better quality.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
